Affordable Access

deepdyve-link
Publisher Website

Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.

Authors
  • Nordestgaard, Børge G
  • Kontula, Kimmo
  • Benn, Marianne
  • Dahlöf, Björn
  • de Faire, Ulf
  • Edelman, Jonathan M
  • Eliasson, Erik
  • Fyhrquist, Frej
  • Hille, Darcy A
  • Ibsen, Hans
  • Lyle, Paulette A
  • Berg, Kåre
  • Sandberg, Mia
  • Sethi, Amar A
  • Wong, Peggy H
  • Os, Ingrid
Type
Published Article
Journal
Pharmacogenetics and Genomics
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Feb 01, 2010
Volume
20
Issue
2
Pages
77–85
Identifiers
DOI: 10.1097/FPC.0b013e328333f70b
PMID: 20065889
Source
Medline
License
Unknown

Abstract

ACE insertion/deletion and 12 other polymorphisms of hypertension susceptibility genes did not affect blood pressure reduction, heart rate reduction, or cardiovascular events in patients with hypertension and LVH, or treatment differences between losartan and atenolol on these endpoints. These results suggest that the observed effects of losartan versus atenolol in the Losartan Intervention for Endpoint reduction in hypertension study do not depend on ACE and 12 other polymorphisms of hypertension susceptibility genes.

Report this publication

Statistics

Seen <100 times